{
  "id" : "eod_primary_tumor_v9_52408",
  "algorithm" : "eod_public",
  "version" : "3.2",
  "name" : "EOD Primary Tumor V9",
  "title" : "EOD Primary Tumor",
  "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Diffuse Pleural Mesothelioma**, from the AJCC Cancer Staging System Version 9 (2025). Used with permission of the American College of Surgeons, Chicago, Illinois.",
  "last_modified" : "2024-05-18T12:11:00.263Z",
  "definition" : [ {
    "key" : "eod_primary_tumor",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  }, {
    "key" : "eod_2018_t",
    "name" : "EOD 2018 T",
    "type" : "ENDPOINT"
  }, {
    "key" : "ss2018_t",
    "name" : "SS2018 T",
    "type" : "ENDPOINT"
  } ],
  "rows" : [ [ "000", "In situ, intraepithelial, noninvasive", "VALUE:88", "VALUE:IS" ], [ "050", "**CLINICAL ASSESSMENT ONLY**\n\nIpsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) WITH\n* Psum less than or equal to 12 mm AND\n* NO involvement of the fissure\n\nConfined to pleura (mesothelioma), NOS, clinically\nLocalized NOS, clinically", "VALUE:T1", "VALUE:L" ], [ "100", "**PATHOLOGICAL ASSESSMENT ONLY**\n\nIpsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) involved\nWITHOUT involvement of the fissure (*See code 300 for fissure involvement*)\n\nConfined to pleura (mesothelioma), NOS, pathologically\nLocalized, NOS, pathologically", "VALUE:T1", "VALUE:L" ], [ "200", "**CLINICAL ASSESSMENT ONLY**\n\nIpsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) WITH\n*Psum less than or equal to 12 mm, and WITH any of the following\n  * involvement of the fissure (Fmax greater than 5 mm)\n  * mediastinal fat invasion\n  * solitary area of chest wall soft tissue invasion\n\nOR\nIpsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) involved WITH\n* Psum greater 12 mm but less than or equal to 30, and WITH or WITHOUT  any of the following\n  * involvement of the fissure (Fmax greater than 5 mm)\n  * mediastinal fat invasion\n  * solitary area of chest wall soft tissue invasion", "VALUE:T2", "VALUE:RE" ], [ "300", "**PATHOLOGICAL ASSESSMENT ONLY**\n\nIpsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) involved\nWITH any of the following\n* Confluent visceral pleural tumor (including any involvement of interlobar fissure)\n* Contiguous lung involvement\n* Diaphragm (diaphragmatic muscle) (non-transmural invasion)\n* Fissure\n* Lung (ipsilateral) parenchyma (direct extension)\n* Nodule(s) beneath visceral pleural surface (ipsilateral pleura)", "VALUE:T2", "VALUE:RE" ], [ "400", "**CLINICAL ASSESSMENT ONLY**\n\nIpsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) involved\n* Psum > 30 mm WITH or WITHOUT\n  * involvement of the fissure (Fmax > 5 mm)\n  * mediastinal fat invasion\n  * solitary area of chest wall soft tissue invasion", "VALUE:T3", "VALUE:RE" ], [ "500", "**PATHOLOGICAL ASSESSMENT ONLY**\n\nIpsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) involved\nWITH or WITHOUT fissure \nWITH any of the following\n* Adjacent (connective) tissue, NOS\n* Endothoracic fascia\n* Mediastinal fat\n* Pericardium, non-transmural or NOS\n* Solitary focus of tumor extending into the chest wall\n\nLocally advanced, potentially resectable tumor", "VALUE:T3", "VALUE:RE" ], [ "600", "Ipsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) involved\nWITH any of the following\n- Chest wall bony invasion (rib) \n- Diffuse chest wall invasion\n- Pericardium (extension through to the internal surface WITHOUT pericardial effusion)\n\nLocally advanced, technically unresectable tumor", "VALUE:T4", "VALUE:RE" ], [ "700", "Ipsilateral pleural (diaphragmatic, parietal, mediastinal, and viscera) involved \nWITH any of the following\n- Brachial plexus\n- Cervical (neck) tissues\n- Contralateral pleura (direct contiguous extension)\n- Intra-abdominal organs\n- Mediastinal organs (direct contiguous extension)\n  - Esophagus\n  - Great vessels\n  - Heart (muscle)\n  - Myocardium\n  - Spine\n  - Trachea\n- Pericardium (direct extension through to the internal surface WITH pericardial effusion)\n- Peritoneum (direct transdiaphragmatic extension of tumor)\n\nFurther contiguous extension", "VALUE:T4", "VALUE:D" ], [ "800", "No evidence of primary tumor", "VALUE:T0", "VALUE:U" ], [ "999", "Unknown; extension not stated\nPrimary tumor cannot be assessed\nNot documented in medical record\n\nDeath Certificate Only", "VALUE:TX", "VALUE:U" ] ],
  "coding_guidelines" : "**Note 1: Ipsilateral pleura definition**\n* Ipsilateral pleura includes diaphragmatic pleura, mediastinal pleura, parietal pleura, and visceral pleura\n\n**Note 2: CLINICAL AND PATHOLOGICAL codes**\n* This schema has primary tumor codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.\n* **CLINICAL** assessment only codes (050, 200, 400) are used when there is a clinical work up only and there is no surgical resection of the primary tumor or site. \n*Exception:* If patient has neoadjuvant therapy, and the clinical assessment is greater than the pathological assessment, then the clinical assessment code would take priority\n\n* **PATHOLOGICAL** assessment only codes (100, 300, 500) are used when\n  * Primary tumor or site surgically resected \n\n* Remaining codes (no designation of **CLINICAL** or **PATHOLOGICAL** only assessment) can be used based on clinical and/or pathological information\n\n**Note 3: Clinical evaluation: Psum and Fmax categories**\n* Clinical evaluation for Pleura is now based on Psum or Fmax categories for localized or regional, but potentially resectable tumors. \n  * Psum, which is defined as pmax1 + pmax2 + pmax3 (sum of 3 measurements of maximal pleural thickness measured on axial images along the chest wall or mediastinum in each of the three division of the chest-upper, middle and lower divided by two lines one at the top of the aortic arch and the second drawn at the top of the atria)\n* Fmax=maximal thickness of pleural tumor along the fissures measured on sagittal images\n* See codes 050, 200, 400 for specific definitions"
}